Clinical Trials on Gastroesophageal Reflux in Mexico

Total 43 results

EndoStim Inc.

Unknown

Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD

Gastroesophageal Reflux Disease

Chile, Colombia, India, Mexico, Netherlands, New Zealand, United Kingdom
Coordinación de Investigación en Salud, Mexico

Recruiting

Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Mexico
Coordinación de Investigación en Salud, Mexico

Completed

Antireflux Ablation Therapy (ARAT) for Gastroesophageal Reflux Treatment (ARAT)

Gastro Esophageal Reflux

Mexico
Takeda

Withdrawn

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

Pediatric Gastroesophageal Reflux Disease

United States, Italy, Israel, Mexico, Poland
Coordinación de Investigación en Salud, Mexico

Enrolling by invitation

ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia (ARAT)

Gastroesophageal Reflux | Achalasia

Mexico
Instituto Mexicano del Seguro Social

Recruiting

Mandatory Hiatoplasty in Sleeve Gastrectomy for Gastro-Esophageal Reflux Disease

Gastroesophageal Reflux | Postgastrectomy Syndromes

Mexico
Takeda

Completed

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Gastroesophageal Reflux Disease (GERD)

United Kingdom, Australia, Belgium, Spain, Austria, Germany, Argentina, Brazil, Canada, France, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Mexico, Poland, Portugal, Singapore, South Africa, Switzerland, Taiwan
Takeda

Recruiting

A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children

Gastroesophageal Reflux Disease (GERD)

United States, Lithuania, Mexico, Canada, Colombia, Poland
Takeda

Completed

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

Gastroesophageal Reflux Disease | Erosive Esophagitis

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Gastroesophageal Reflux Disease

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Shire

Completed

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Czechia, Germany, Latvia, Poland, Romania
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

United States
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
AstraZeneca

Completed

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma... and other conditions

United States
Seagen Inc.
RemeGen Co., Ltd.

Recruiting

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Stomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast Neoplasms

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Gastric Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Si... and more
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Canada, Czech Republic, Lithuania, Slovakia, Latvia, Estonia, Australia
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, South Africa, Canada, Peru, New Zealand, Australia, Lithuania, Slovakia, Hungary, Latvia, Germany, Czech Republic
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction

United States
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Germany, Italy, Spain, United States, Hungary, Russian Federation, Poland, Belgium, Netherlands, France, Czechia, Mexico, Argentina, Canada, Denmark, Finland, Israel, Japan, Puerto Rico, United Kingdom
Axsome Therapeutics, Inc.

Unknown

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 (CREATE-1)

Reflex Sympathetic Dystrophy | Complex Regional Pain Syndrome

United States, United Kingdom, Australia, Canada
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Japan, China, Netherlands, Spain, Germany, United Kingdom, Malaysia, Taiwan, Portugal, France, Italy, Australia, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Poland, Brazil, ... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Esophageal Squamous Cell Carcinoma (ESCC) | Gastroesophageal Junction Carcinoma (GEJC) | Esophageal Adenocarcinoma (EAC)

China, Canada, United States, Argentina, Belgium, Brazil, Chile, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Philippines, Portugal, Romania, Russian Federation and more
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Terminated

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Melanoma | Small Cell Lung Cancer | Prostate Cancer | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous

United States, Korea, Republic of, Italy, United Kingdom, Australia, Taiwan

Clinical Trials on Gastroesophageal Reflux in Mexico

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations